Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis
Authors' conclusion
PDAC-DM and type 2 diabetes are metabolically distinct, with different defects responsible for hyperglycaemia. PDAC-DM is characterised predominantly by insulin deficiency and displays higher insulin sensitivity than type 2 diabetes. There are also differences in alpha cell regulation and insulin clearance compared with type 2 diabetes. These findings identify biological characteristics that may have implications for individualised treatment of PDAC-DM and guide diagnostic biomarker discovery for early PDAC diagnosis.
Study context
- Population
- Adults with cancer treatment-naive PDAC-DM or T2D, diabetes onset within 3 years
- Participants
- 28 vs 97
- Exposure
- PDAC-DM vs T2D
- PDAC-DMn = 28
- Type 2 diabetesn = 97reference
- Outcome
- Glucose homeostasis measures (mixed-meal tolerance test)
Methodological detailsmixed-meal tolerance tests
- Mixed-meal tolerance tests
Main finding
As reported in the abstract
Insulin sensitivity (Matsuda index) greater with PDAC-DM vs T2D
≈2.5-fold
Insulin secretion (insulinogenic index) lower with PDAC-DM vs T2D
≈81%
Beta cell function (oral disposition index) lower with PDAC-DM vs T2D
≈40%
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →